Dennis and Linda Fenton Establish Matthew and Kathy Croughan Endowed Scholarship in Bioprocessing

A generous $1M gift from Dennis and Linda Fenton to Keck Graduate Institute (KGI) has established the Matthew and Kathy Croughan Endowed Scholarship in Bioprocessing.

Through this gift, the endowed scholarship will increase access to careers in the biopharmaceutical industry for underprivileged women. Eligible students may be enrolled in either the Master of Business and Science concentration in Bioprocessing or the Master of Engineering in Biopharmaceutical Processing programs.

These scholarship dollars will be used to attract and retain female minority students with a demonstrated financial need who are interested in pursuing a career in bioprocessing.

The Fentons are establishing this endowment in honor of their friends, Matthew and Kathy Croughan. This endowed scholarship recognizes the contributions that Matt has made to bioprocessing at KGI and his role as a leader in the biopharmaceutical industry. Matt was the founding Director of the Amgen Bioprocessing Center and the first recipient of the George B. and Joy Rathmann Professorship.

“Linda and I are proud to have worked closely with Matt and Kathy to establish the Amgen Bioprocessing Center at KGI in 2006,” said Dennis Fenton. “As the initial recipient of the George B. and Joy Rathmann Professorship, Matt has mentored many leaders for the bioprocessing industry.”

“We have endowed this scholarship to honor their commitment and provide opportunities for students who would benefit from KGI programs but may not otherwise be able to attend.”

The Matthew and Kathy Croughan Endowed Scholarship in Bioprocessing will support one to two annual scholarships. Award amounts may vary based on endowment value at awarding and determination of student need by KGI Financial Aid.

“Recruiting even more top students to KGI’s bioprocessing program, including those who could not otherwise afford to attend, will help ensure we successfully scale up and deliver lifesaving drugs and vaccines,” said Matt Croughan. “This is important for every patient, every time—no matter how short the timelines are or how big the demands.”